You can buy or sell IDXG and other stocks, options, ETFs, and crypto commission-free!
Interpace Diagnostics Group, Inc. operates as an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. Read More The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.
Parsippany, New Jersey
52 Week High
52 Week Low
Seeking AlphaMay 14
Interpace Diagnostics Group, Inc. CEO Jack Stover on Q1 2019 Results - Earnings Call Transcript
Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Q1 2019 Earnings Conference Call May 13, 2019 4:30 PM ET Company Participants Jack Stover - President & CEO Jim Early - CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Yi Chen - H.C. Wainwright Benjamin Haynor - Alliance Global Partners Naureen Quibria - Maxim Group François Brisebois - LaidLaw Capital Markets Operator Greetings, and welcome to the Interpace Diagnostics Group First Quarter 2019 Financial Results Conference Call. ...
Yahoo FinanceMay 13
Interpace Diagnostics Reports First Quarter 2019 Financial Results and Provides Business Update
Quarterly Revenue Grew to $6.0 Million, a 25% Increase Year-over-Year Annual 2019 Revenue Guidance of $27 to $28 Million, a 25% Increase Conference Call and Webcast Monday May 13, 2019 at 4:30 pm ET Parsippany, NJ, May 13, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG), a fully integrated bioinformatics and commercial molecular diagnostic company, today announced financial results for the first quarter ended March 31, 2019, and reviewed recent business progress. “We had a strong start...
Interpace Diagnostics BarreGEN® Data to be Presented at Digestive Disease Week
Company to Host Fellowship and Key Opinion Leader Programs PARSIPPANY, NJ, May 09, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) announced today that data from an independent study, which showed that BarreGEN® performed effectively as a biomarker tool for predicting risk of developing more advanced stages of disease prior to visible appearance of advanced histology, will be presented at the annual Digestive Disease Week® ("DDW"). The meeting will be held in San Diego, CA on...
-$0.06 per share
-$0.10 per share